FELDAN

Now

Refused for now — an office action was mailed 26 Jun 2026.

A response is due by 26 Dec 2026; with no response the application is abandoned.

What this means for you

Not registered yet, but its 31 Mar 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

79450804

Mark type

Word mark

Filed

31 Mar 2026

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases, chronic wound, skin cancer, precancerous skin lesions, skin fibrosis and treatment of acne; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases, disorders and infections; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), parkinson's disease, multiple sclerosis, myasthenia gravis, huntington's disease; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia and obesity; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for use in hematology, namely for the treatment of blood disorders; pharmaceutical preparations for use in the treatment of musculoskeletal diseases and disorders; pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; cardiovascular pharmaceutical preparations; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of endocrine diseases, namely, glucagonoma; dermatological pharmaceutical preparations for the treatment of psoriasis; dermatological pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the diagnosis of oncological diseases and disorders; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations.
• Class 042 — Scientific and technological services: Pharmaceutical research and development; research and development in the fields of pharmaceuticals, biotechnology, cell therapies, drug delivery technologies, dermatology, oncology, cardiology, gastroenterology, endocrinology, genitourinary, ophthalmology, nephrology, pulmonology, vascular system, and ischemia; providing medical scientific information in the fields of pharmaceuticals, biotechnology, cell therapies, drug delivery technologies, dermatology, oncology, cardiology, gastroenterology, endocrinology, genitourinary, ophthalmology, nephrology, pulmonology, vascular system, and ischemia; drug discovery services.

Owner

• FELDAN BIO INC., XP

Prosecution history

• 09 Nov 2026 — ASSIGNED TO LIE
• 27 Jun 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
• 26 Jun 2026 — NON-FINAL ACTION WRITTEN
• 26 Jun 2026 — ASSIGNED TO EXAMINER
• 05 Jun 2026 — APPLICATION FILING RECEIPT MAILED
• 05 Jun 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 28 May 2026 — SN ASSIGNED FOR SECT 66A APPL FROM IB